Sigma Life Science enters genetically modified cell market
Engineered cell lines exploit CompoZr zinc finger nuclease technology
Sigma Life Science, the biological products and research services business of Sigma-Aldrich Corporation, has released a pioneering range of engineered mammalian cell lines. This new product range combines Sigma's proprietary CompoZr zinc finger nuclease (ZFN) technology with its gene silencing expertise to offer tools for drug discovery, compound screening and fundamental research applications. These new products include immortalised cell lines for a broad spectrum of applications.
By exploiting the genomic editing capabilities of ZFNs, Sigma says its scientists can rapidly manufacture stable cell lines with precise, well-characterised genetic manipulations.
‘CompoZr ZFN technology is a significant breakthrough for cell-based research. It enables scientists to generate precisely controlled additions, deletions and modifications to the genome of a living cell,’ said Supriya Shivakumar, global commercial marketing manager for Functional Genomics at Sigma Life Science.
The programme will use ZFNs to incorporate and develop cell lines with a variety of cellular markers that will assist in compound screening studies and biochemical pathway analysis, as well as specific isogenic lines designed to advance colorectal and breast cancer research.
In addition, Sigma offers a custom cell line engineering service, creating bespoke cell lines to match a researcher's application.